Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors.

Chromosome 9 allelic losses have been reported as a frequent and early event occurring in bladder cancer. It has been postulated that a candidate tumor suppressor gene may reside on this chromosome, alterations of which may lead to the development of a subset of superficial bladder tumors. More recently, the involvement of two different regions harboring suppressor loci, one on each of both chromosome 9 arms, has been proposed. We undertook the present study with the objectives of better defining the deleted regions of chromosome 9 in bladder tumors, as well as evaluating the frequency of microsatellite alterations affecting certain loci on this chromosome in urothelial neoplasia. Seventy-three primary bladder tumors were analyzed using a set of highly polymorphic markers, and results were correlated with pathological parameters associated with poor clinical outcome. We observed that, overall, 77% of the tumors studied showed either loss of heterozygosity for one or more chromosome 9 markers and/or microsatellite abnormalities at chromosome 9 loci. Detailed analyses showed that two regions, one on 9p at the interferon cluster, and the other on 9q associated with the q34.1-2 bands, had the highest frequencies of allelic losses. Furthermore, Ta lesions appeared to present mainly with 9q abnormalities, while T1 tumors displayed a mixture of aberrant 9p and 9q genotypes. These observations indicate that loss of heterozygosity of 9p may be associated with the development of superficial tumors with a more aggressive biological behavior or, alternatively, they may be related to early disease progression. In addition, microsatellite alterations were documented in over 40% of amplified cases. Taken together, these data suggest that two different tumor suppressor gene loci on chromosome 9 are involved as tumorigenic events in bladder cancer and that chromosome 9 microsatellite alterations are frequent events occurring in urothelial neoplasia.

[1]  H. Wolf,et al.  Activity of the human blood group ABO, Se, H, Le, and X gene-encoded glycosyltransferases in normal and malignant bladder urothelium. , 1988, Cancer research.

[2]  C. Cordon-Cardo,et al.  Molecular Genetic Alterations of Chromosome 17 and p53 Nuclear Overexpression in Human Bladder Cancer , 1993, Diagnostic molecular pathology : the American journal of surgical pathology, part B.

[3]  D. Sidransky,et al.  Evidence for two bladder cancer suppressor loci on human chromosome 9. , 1993, Cancer research.

[4]  C. Cordon-Cardo,et al.  Genetic alterations in bladder cancer , 1993, The Lancet.

[5]  R. Cote,et al.  Two molecular pathways to transitional cell carcinoma of the bladder. , 1994, Cancer research.

[6]  J. Rowley,et al.  Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[7]  Darryl Shibata,et al.  Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis , 1993, Nature.

[8]  O. Olopade,et al.  Mapping of the shortest region of overlap of deletions of the short arm of chromosome 9 associated with human neoplasia. , 1992, Genomics.

[9]  Nitin R. Patel,et al.  A Network Algorithm for Performing Fisher's Exact Test in r × c Contingency Tables , 1983 .

[10]  Robin J. Leach,et al.  Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer , 1993, Cell.

[11]  L. Aaltonen,et al.  Microsatellite instability is associated with tumors that characterize the hereditary non-polyposis colorectal carcinoma syndrome. , 1993, Cancer research.

[12]  M. Skolnick,et al.  Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. , 1992, Science.

[13]  References , 1971 .

[14]  C. Cordon-Cardo,et al.  Molecular genetic alterations in superficial and locally advanced human bladder cancer. , 1991, Cancer research.

[15]  M. Melamed,et al.  Blood group-related antigens in human urothelium: enhanced expression of precursor, LeX, and LeY determinants in urothelial carcinoma. , 1988, Cancer research.

[16]  S. Lerner,et al.  Role of chromosome 9 in human bladder cancer. , 1993, Cancer research.

[17]  F. Askin,et al.  Frequent loss of chromosome 9 in human primary non-small cell lung cancer. , 1994, Cancer research.

[18]  R. Takahashi,et al.  Accumulated allelic losses in the development of invasive urothelial cancer , 1993, International journal of cancer.

[19]  M. Knowles,et al.  Preliminary mapping of the deleted region of chromosome 9 in bladder cancer. , 1993, Cancer research.

[20]  P. Nichols,et al.  Allelic losses of chromosomes 9, 11, and 17 in human bladder cancer. , 1990, Cancer research.

[21]  M. Knowles,et al.  Initiation of bladder cancer may involve deletion of a tumour-suppressor gene on chromosome 9. , 1993, Oncogene.

[22]  D. Evans,et al.  Location of gene for Gorlin syndrome , 1992, The Lancet.

[23]  O. Olopade,et al.  Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. , 1993, Cancer research.

[24]  Henrik Clausen,et al.  Molecular genetic basis of the histo-blood group ABO system , 1990, Nature.